Fig. 2. Pre-clinical studies in mice using multi-modality imaging of tumor metabolism to guide targeted therapies (A) Overview of longitudinal 18F-FDG PET/CT and BLI imaging of genetically engineered mouse model of lung cancer at 2, 6, 8 and 10 weeks post tumor induction. (B) Representative histology performed on mice imaged with PET/CT and BLI. Tumors were stained with H&E or Glut1 as a surrogate biomarker of glucose uptake or P-S6, a surrogate biomarker of mTORC1 signaling. (C) Representation of the PI3K/AKT/mTOR signaling pathway and its regulation of cellular growth and metabolism. In pink are metabolic based drugs and targeted therapies that target this pathway. (D) Representation of 18F-FDG PET/CT guided studies in mice measuring metabolic response to the catalytic mTOR kinase inhibitor (mTORi). Top panel shows representative 18F-FDG PET/CT images of mice untreated vs those treated with mTORi. Bottom panel shows representative immunohistochemical staining of lung tumors for the mTORC1 substrate.
© Biomolecules & Therapeutics
